Similar articles for PMID: 27466550

Year	Number of Results
2005	1
2008	1
2009	2
2010	1
2011	6
2012	14
2013	15
2014	13
2015	14
2016	11
2017	7
2018	3
2019	3
2020	1
2021	3
2022	1

1

Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.

Ooi H, Chen CY, Hsiao YC, Huang WS, Hsieh BT. Ooi H, et al. Anticancer Res. 2016 Aug;36(8):4313-20. Anticancer Res. 2016. PMID: 27466550

2

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y. Zhang H, et al. Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19. Acad Radiol. 2013. PMID: 22999369

3

Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Chen HH, et al. Radiology. 2012 Aug;264(2):559-66. doi: 10.1148/radiol.12111148. Epub 2012 Jun 12. Radiology. 2012. PMID: 22692034

4

Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.

Liu H, Chen P, Wroblewski K, Hou P, Zhang CP, Jiang Y, Pu Y. Liu H, et al. Nucl Med Commun. 2016 Jan;37(1):50-6. doi: 10.1097/MNM.0000000000000396. Nucl Med Commun. 2016. PMID: 26426969 Free PMC article. Clinical Trial.

5

New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.

Melloni G, Gajate AM, Sestini S, Gallivanone F, Bandiera A, Landoni C, Muriana P, Gianolli L, Zannini P. Melloni G, et al. Eur J Surg Oncol. 2013 Nov;39(11):1254-61. doi: 10.1016/j.ejso.2013.07.092. Epub 2013 Aug 13. Eur J Surg Oncol. 2013. PMID: 23948705

6

Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.

Wang D, Koh ES, Descallar J, Pramana A, Vinod SK, Ho Shon I. Wang D, et al. Asia Pac J Clin Oncol. 2016 Dec;12(4):349-358. doi: 10.1111/ajco.12587. Epub 2016 Aug 23. Asia Pac J Clin Oncol. 2016. PMID: 27550522

7

Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.

Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T. Zaizen Y, et al. Eur J Radiol. 2012 Dec;81(12):4179-84. doi: 10.1016/j.ejrad.2012.07.009. Epub 2012 Aug 9. Eur J Radiol. 2012. PMID: 22884163

8

Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.

Koh YW, Lee SJ, Park SY. Koh YW, et al. Lung Cancer. 2017 Feb;104:31-37. doi: 10.1016/j.lungcan.2016.12.003. Epub 2016 Dec 15. Lung Cancer. 2017. PMID: 28212997

9

Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.

Yıldırım F, Yurdakul AS, Özkaya S, Akdemir ÜÖ, Öztürk C. Yıldırım F, et al. Clin Respir J. 2017 Sep;11(5):602-611. doi: 10.1111/crj.12391. Epub 2015 Oct 16. Clin Respir J. 2017. PMID: 26434685

10

Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.

Winther-Larsen A, Fledelius J, Sorensen BS, Meldgaard P. Winther-Larsen A, et al. Lung Cancer. 2016 Apr;94:81-7. doi: 10.1016/j.lungcan.2016.01.024. Epub 2016 Feb 8. Lung Cancer. 2016. PMID: 26973211

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed